Kisspeptin and Gynecological Cancer

Bushangqing Liu(Imperial College London)
Unknown
July 4, 2020
10.1145/3403782.3403796
Cited by 1

Abstract

Background: Kisspeptin was identified in 1996 and it was known as a suppressor of metastatic malignant tumors. Kisspeptin and its receptor KISS1R have been identified as potential prognostic or therapeutic markers in cancers. Recent study suggested that kisspeptin plays an important role in gynecological cancer, including breast cancer, ovarian cancer, and endometrium cancer.

Related Papers

Discovery of a receptor related to the galanin receptors
Dennis K Lee, Tuan Nguyen, Gary P. O’Neill et al.|FEBS Letters|1999|498
KiSS-1 Represses 92-kDa Type IV Collagenase Expression by Down-regulating NF-κB Binding to the Promoter as a Consequence of IκBα-induced Block of p65/p50 Nuclear Translocation
Chunhong Yan, Heng Wang, Douglas D. Boyd|Journal of Biological Chemistry|2001|198
Metastin and its variant forms suppress migration of pancreatic cancer cells
Toshihiko Masui, Ryuichiro Doi, Tomohiko Mori et al.|Biochemical and Biophysical Research Communications|2004|136
KiSS1 Suppresses Metastasis in Human Ovarian Cancer via Inhibition of Protein Kinase C Alpha
Ying Jiang, Michael Berk, Lisam Shanjukumar Singh et al.|Clinical & Experimental Metastasis|2005|121
Kisspeptin-10, a KISS1-Derived Decapeptide, Inhibits Tumor Angiogenesis by Suppressing Sp1-Mediated VEGF Expression and FAK/Rho GTPase Activation
Sung‐Gook Cho, Zhengfang Yi, Xiufeng Pang et al.|Cancer Research|2009|106